Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$207.91 -0.1%	$194.10	$163.81 ▼ $218.66	$367.28B	0.5	6.59 million shs	4.52 million shs
IRWD Ironwood Pharmaceuticals	$1.32 +4.8%	$0.86	$0.53 ▼ $5.21	$214.41M	0.33	2.80 million shs	900,930 shs
RIGL Rigel Pharmaceuticals	$39.31 -1.1%	$25.37	$12.66 ▼ $43.72	$705.22M	1.21	311,775 shs	827,845 shs
ZBIO Zenas BioPharma	$16.26 -2.7%	$13.68	$5.83 ▼ $26.25	$684.71M	N/A	181,715 shs	99,604 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.13%	-0.23%	+10.49%	+12.32%	+6.30%
IRWD Ironwood Pharmaceuticals	-0.79%	+14.55%	+57.72%	+99.52%	-74.29%
RIGL Rigel Pharmaceuticals	-4.54%	-3.94%	+98.75%	+103.43%	+200.76%
ZBIO Zenas BioPharma	-1.71%	+2.39%	+1.58%	+67.10%	+1,670,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.6992 of 5 stars	2.5	4.0	3.3	3.9	3.3	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.593 of 5 stars	3.1	5.0	0.0	3.4	3.8	0.8	1.9
RIGL Rigel Pharmaceuticals	1.6191 of 5 stars	1.2	1.0	0.0	0.0	2.6	1.7	3.1
ZBIO Zenas BioPharma	1.5209 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.96	Moderate Buy	$214.95	3.39% Upside
IRWD Ironwood Pharmaceuticals	2.14	Hold	$4.94	274.24% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-2.82% Downside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	125.50% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, RIGL, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
8/1/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$250.00 ➝ $255.00
8/1/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$216.00 ➝ $227.00
8/1/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$227.00 ➝ $236.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$58.33B	6.30	$14.90 per share	13.95	($0.08) per share	-2,598.83
IRWD Ironwood Pharmaceuticals	$308.52M	0.69	$0.05 per share	25.68	($1.90) per share	-0.69
RIGL Rigel Pharmaceuticals	$179.28M	3.93	$1.02 per share	38.58	$4.57 per share	8.60
ZBIO Zenas BioPharma	$15M	45.65	N/A	N/A	$5.69 per share	2.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	99.00	14.87	1.34	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.05	N/A	5.28	N/A	-2.25%	-2.46%	2.19%	11/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.27	37.44	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	-59.21%	-50.56%	11/11/2025 (Estimated)

Latest IRWD, ABBV, RIGL, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	$5.00 million	N/A
8/7/2025	Q2 2025	IRWD Ironwood Pharmaceuticals	-$0.02	$0.14	+$0.16	$0.14	$62.02 million	$85.24 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.16%	N/A	312.38%	53 Years
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	$0.05	0.30%	N/A	N/A	N/A

Latest IRWD, ABBV, RIGL, and ZBIO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
IRWD Ironwood Pharmaceuticals	N/A	0.82	0.82
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
ZBIO Zenas BioPharma	N/A	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
IRWD Ironwood Pharmaceuticals	N/A
RIGL Rigel Pharmaceuticals	66.23%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
IRWD Ironwood Pharmaceuticals	12.70%
RIGL Rigel Pharmaceuticals	9.48%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
IRWD Ironwood Pharmaceuticals	220	162.43 million	141.81 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
ZBIO Zenas BioPharma	N/A	42.11 million	35.16 million	N/A

IRWD, ABBV, RIGL, and ZBIO Headlines

Recent News About These Companies

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

August 26 at 7:05 AM | globenewswire.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Down 7.2% - Here's What Happened

August 21, 2025 | marketbeat.com

We Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth Carefully

August 20, 2025 | finance.yahoo.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?

August 20, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Zenas BioPharma

August 17, 2025 | marketbeat.com

What is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?

August 17, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street Zen

August 17, 2025 | marketbeat.com

Wedbush Has Pessimistic View of Zenas BioPharma Q3 Earnings

August 17, 2025 | americanbankingnews.com

Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday

August 15, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 14, 2025 | marketbeat.com

Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit

August 13, 2025 | msn.com

Zenas BioPharma Reports Q2 2025 Financial Results

August 13, 2025 | tipranks.com

Zenas BioPharma expects cash to fund operations into Q4 of 2026

August 12, 2025 | msn.com

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12, 2025 | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12, 2025 | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRWD, ABBV, RIGL, and ZBIO Company Descriptions

AbbVie NYSE:ABBV

$207.91 -0.15 (-0.07%)

Closing price 03:59 PM Eastern

Extended Trading

$207.86 -0.05 (-0.02%)

As of 05:43 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ironwood Pharmaceuticals NASDAQ:IRWD

$1.32 +0.06 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 -0.01 (-0.38%)

As of 05:37 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$39.31 -0.42 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$39.30 -0.01 (-0.03%)

As of 05:36 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Zenas BioPharma NASDAQ:ZBIO

$16.26 -0.45 (-2.69%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time